Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Dr. Leonard on the Future of PI3K Inhibitors in Follicular Lymphoma

July 7th 2021

John P. Leonard, MD, discusses the future of PI3K inhibitors in follicular lymphoma.

Dr. Leonard on the Potential for Combinations With PI3K Inhibitors in Follicular Lymphoma

July 6th 2021

John P. Leonard, MD, discusses the potential for combination regimens with PI3K inhibitors in follicular lymphoma.

Dr. Kahl on Selecting Between PI3K Inhibitors in Follicular Lymphoma

July 6th 2021

Brad S. Kahl, MD, discusses selecting between PI3K inhibitors in follicular lymphoma.

Long-Term Data Showcase the Clinical Utility of Fixed-Duration Venetoclax/Obinutuzumab in Treatment-Naïve CLL

July 6th 2021

Fixed-duration venetoclax plus obinutuzumab demonstrated prolonged remissions compared with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukemia and comorbidities.

Second-Line Axi-Cel Significantly Improves EFS Over Standard of Care in Relapsed/Refractory LBCL

June 28th 2021

Axicabtagene ciloleucel significantly improved event-free survival by 60% over chemotherapy plus stem cell transplant in the second-line treatment of patients with relapsed or refractory large B-cell lymphoma, meeting the primary end point of the phase 3 ZUMA-7 trial.

Tafasitamab/Lenalidomide Recommended for EU Approval for Relapsed/Refractory DLBCL

June 25th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion in favor of granting conditional marketing authorization to the combination of tafasitamab-cxix and lenalidomide, followed by single-agent tafasitamab, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplant.

177Lu Lilotomab Satetraxten Shows Early Activity in Transplant-Ineligible, Relapsed/Refractory DLBCL

June 24th 2021

The next-generation CD37-directed radioimmunotherapy 177Lu lilotomab satetraxten has showcased early clinical activity with favorable tolerability when used in patients with relapsed/refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation.

Discrepancies Between Real-World Patterns of Care and Recommendations Based on Clinical Trials Exist in MCL

June 23rd 2021

Peter Martin, MD, discusses discrepancies in real-world patterns of care for patients with MCL and what can be done to overcome them.

Loncastuximab Tesirine Continues to Impress in Relapsed/Refractory DLBCL and MCL

June 23rd 2021

Loncastuximab tesirine-lpyl continued to demonstrate promising antitumor activity with an acceptable toxicity profile when used in the treatment of select patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and mantle cell lymphoma.

Oncology Leaves Its Mark on 2020 Research and Development Trends

June 16th 2021

Rates of clinical trial initiation, novel drug development, and collaborative research and development deals were oncology.

Investigators Set Sights on Curative Approaches for Follicular Lymphoma

June 15th 2021

The majority of patients with indolent follicular lymphoma do well with observation and after first-line treatment, but approximately 20% experience disease progression within 2 years of their initial treatment, which is associated with a 50% risk of dying within 5 years. Subsequently, this is an area of unmet need but one in which considerable progress is being made.

Rituximab Biosimilar CT-P10 Demonstrates Real-World Safety, Efficacy in DLBCL

June 14th 2021

The rituximab biosimilar CT-P10 produced response and survival rates that were comparable to those previously reported with the reference product, along with acceptable tolerability, in patients with diffuse large B-cell lymphoma.

Front-MIND Aims to Examine Tafasitamab Triplet in DLBCL

June 14th 2021

Tafasitamab-cxix plus lenalidomide and R-CHOP may have synergistic potential and could represent a potential future treatment option for patients with newly diagnosed diffuse large B-cell lymphoma.

Naratuximab Emtansine/Rituximab Combo Elicits Clinical Activity in Relapsed/Refractory DLBCL

June 12th 2021

The combination of naratuximab emtansine and rituximab yielded deep responses, and a duration of response that was not reached in patients with relapsed or refractory diffuse large B-cell lymphoma.

Real-World Data Highlight Utility of Axi-Cel/Tisa-Cel in DLBCL

June 12th 2021

In the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large b-cell lymphoma in the outpatient setting who are receiving the CAR T-cell therapies prior to failure on 2 prior lines of therapy.

Axi-Cel Provides Durable Responses in Higher-Risk Follicular Lymphoma and MZL, Regardless of POD24 Status

June 11th 2021

Axicabtagene ciloleucel demonstrated significant clinical activity with durable responses in patients with relapsed/refractory indolent non-Hodgkin lymphoma who experienced disease progression within 24 months from initiation of the first anti-CD20–containing chemotherapy, which is a high-risk clinical feature.

Lenalidomide/Rituximab Continues to Improve PFS in iNHL, MCL

June 11th 2021

The combination of lenalidomide and rituximab continued to improve progression-free survival with durable outcomes and a manageable safety profile in patients with indolent B-cell non-Hodgkin lymphomas and mantle cell lymphomas.

Latest in Myeloma, Prostate Cancer, and Lymphoma From ASCO 2021: Drs Neal Shore, Loretta Nastoupil, and Sandy Wong

June 9th 2021

OncLive sits down with Sandy Wong, MD; Neal Shore, MD; and Loretta Nastoupil, MD, to share the the insight on data in multiple myeloma, prostate cancer, and non-Hodgkin lymphoma at the 2021 ASCO Annual Meeting.

C-CAR066 Achieves High Marks in Relapsed/Refractory B-NHL

June 8th 2021

C-CAR066 exhibited a favorable safety profile and promising efficacy in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed with prior CD19 CAR T-cell therapy.

C-CAR039 Demonstrates Promising Efficacy, Safety in Relapsed/Refractory B-NHL

June 8th 2021

The second-generation 4-1BB bi-specific CAR T-cell therapy C-CAR039 improved response rates and showed favorable safety in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.